Physician profile
Jeffrey A Alloway
NPI 1104829332
$45,598.00
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23K · 2020: $13K · 2021: $3,066 · 2022: $5,880 · 2023: $13.10 · 2024: $24.78.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $37.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $37.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $42,852.61 | 2019-2022 | |
| Pfizer INC. | $567.67 | 2019-2020 | |
| Amgen INC. | $525.89 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $386.62 | 2019-2020 | |
| Ucb, INC. | $189.49 | 2019-2020 | |
| Lilly USA, LLC | $180.63 | 2019-2020 | |
| Janssen Biotech, INC. | $147.92 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $103.37 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $96.45 | 2019-2020 | |
| Celgene Corporation | $74.00 | 2019 | |
| Glaxosmithkline, LLC. | $63.22 | 2019 | |
| Genentech USA, INC. | $57.48 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $47.98 | 2019 | |
| Hikma Pharmaceuticals USA | $47.26 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $46.67 | 2019-2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $38.80 | 2019-2020 | |
| Boston Scientific Corporation | $37.88 | 2023-2024 | Wavewriter Alpha Prime 16, Resolution 360 Ultra Clip |
| Alexion Pharmaceuticals, INC. | $35.81 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.63 | 2019-2020 | |
| Medexus Pharma, INC. | $27.39 | 2019 | |
| Depuy Synthes Sales INC. | $15.57 | 2019 | |
| Fidia Pharma USA INC. | $14.87 | 2019 | |
| Merck Sharp & Dohme LLC | $12.79 | 2020 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Alloway listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.